Dabrafenib adn trametinib for BRAF + referactory papillary cacner – pro
Lenvatinib and sorafenib, multi-kinase inhibitors, represent the standard first-line systemic treatment options while cabozantinib is the standard second-line treatment option, for this purpose.
The combination of dabrafenib and trametinib has been studies primarily for anaplastic thryoid cancer, for which it is FDA approve3d. Some literature is available for other thyroid cancer type. .
BRAF mutations are detected in 30%-80% of papillary thyroid cancer (PTC) cases. A retrospective study by Youngkyung Jeon et al demonstrated a high ORR with promising PFS; however, most patients with BRAFV600E-mutated metastatic PTC required a dose reduction. A randomized phase II study by M. Shah et al was well tolerated and obtained high objective response rates with durable responses in pts with progressive BRAF-mutated PTC.
Jeon Y, Park S, Lee SH, Kim TH, Kim SW, Ahn MJ, Jung HA, Chung JH. Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer. Cancer Res Treat. 2024 Oct;56(4):1270-1276. doi: 10.4143/crt.2023.1278. Epub 2024 Mar 6. PMID: 38453274; PMCID: PMC11491250.
M. H. Shah et al, Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. Meeting Abstract: 2017 ASCO Annual Meeting Head and Neck Cancer May 30, 2017